Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644 1645 1674 1699
This examiner grants 66% of resolved cases
Yunsoo Kim is a patent examiner in Tech Center 1600, specifically working within Art Unit 1641. This examiner has overseen 946 resolved cases, which provides a substantial statistical foundation for analyzing their historical prosecution patterns. These 946 resolved cases encompass all applications that have reached a final decision under their review in Art Unit 1641 and Tech Center 1600.
The data reveals an allowance rate of 65.9 percent, which reflects the proportion of applications that are successfully granted. The median days to allowance for these cases is 1323. This duration of 1323 days represents the typical timeline for reaching a favorable outcome. The 65.9 percent allowance rate serves as a primary benchmark for applicants when planning their prosecution strategy.
The interview lift for this examiner is 34.3 percent. This 34.3 percent lift indicates that conducting an interview is associated with an increase in the probability of allowance compared to the baseline rate of 65.9 percent. Given the median days to allowance of 1323, the 34.3 percent interview lift suggests that direct communication with the examiner is a valuable tool for improving the likelihood of a successful grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18600194 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 17542138 | METHOD FOR REGENERATION OF AN OVERLOAD CHROMATOGRAPHY COLUMN | Final Rejection | Genentech, Inc. |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 19217541 | PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18592388 | ANTI-FEL D1 ANTIBODY FORMULATIONS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18105772 | Stabilized Formulations Containing Anti-IL-33 Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18444288 | PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY | Non-Final OA | NOVARTIS AG |
| 18011412 | TYPE 2 CYTOKINES AS PREDICTORS OF DISEASE SEVERITY AND/OR AS THERAPEUTIC TARGETS FOR COVID-19 | Non-Final OA | University of Virginia Patent Foundation |
| 18300339 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA AMYLOID ANTIBODIES | Non-Final OA | Biogen MA Inc. |
| 18257600 | CONJUGATED AFLATOXIN B TO PROTECT AGAINST MYCOTOXICOSIS | Final Rejection | Intervet Inc. |
| 17335680 | Method for the reduction of host cell proteins in affinity chromatography | Non-Final OA | Hoffmann-La Roche Inc. |
| 18261146 | METHODS AND PLATFORMS FOR ELICITING AN IMMUNE RESPONSE IN THE TREATMENT OF CANCER AND COMPOSITIONS AND VACCINES RELATING THERETO | Non-Final OA | University of Maryland, College Park |
| 17928561 | ANTIBODY FORMULATIONS AND USES THEREOF | Final Rejection | Amgen Inc. |
| 18046450 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY | Final Rejection | Takeda Pharmaceutical Company Limited |
| 16817671 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18243767 | STABILIZED ANTIBODY PROTEIN SOLUTIONS | Non-Final OA | Arecor Limited |
| 18620109 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18287240 | AN ANTI-TSLP FAB WITH IMPROVED STABILITY | Non-Final OA | MEDIMMUNE LIMITED |
| 18176155 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS | Final Rejection | Omeros Corporation |
| 16640914 | ANTIBODY-DRUG CONJUGATE PREPARATION AND LYOPHILIZATION FOR SAME | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy